The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- FDA Commissioner Hamburg’s Farewell Address: Defense Of Approval Standard Framed As Rebuttal To Alzheimer Advocates Mar. 27, 2015
- White House Antibiotic Report Supports Push Incentives Over Pull; “Wild Card” Patent, Other Prizes Not Included Mar. 27, 2015
- Specialty Tier Cost-Sharing Bill Would Limit Beneficiary Co-Pays for Specialty Drugs to Same Level of “Non-Preferred Brand” Tier Mar. 26, 2015
See More Research Notes